Gilead and Merck Split Trial Results in Busy Biotech Week

Two of the largest names in drug development, Gilead and Merck, delivered a split verdict on their pipelines this week, with one clinical trial succeeding and another failing, according to STAT News. The mixed outcomes underscore how unpredictable late-stage testing remains even for well-capitalized incumbents, where a single readout can move billions in market value.

The results landed amid a heavy stretch of industry activity. STAT News reported that AstraZeneca is pushing forward with a GLP-1 pill, positioning it to compete in the oral weight-loss market that has become the most contested arena in pharma. GSK, meanwhile, agreed to acquire a cancer startup for $10.6 billion, signaling that big pharma continues to buy its way into oncology pipelines rather than build them in-house.

For investors and operators, the through-line is clear: large drugmakers are placing concentrated bets on obesity and cancer, the two categories with the biggest commercial upside, while accepting that individual trials will still produce both wins and flops.